不同年龄组小细胞肺癌的临床特征与预后影响因素分析

doi:10.3969/j.issn.1006-5253.2022.04.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (5098 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical characteristics and prognostic factors of patients with small cell lung-cancer- in different age groups, and to provide reference for improving the prognostic status of patients.Methods In the SEER database, qualified small cell lung cancer patients were selected and divided into groups using X-tile software to find out the age cutoff value and group them according to age. Chi-square test and rank-sum test were used for the comparison of clinical characteristics between groups, time series test was used for the difference of survival curve, multivariate Cox proportional hazard model was used to analyze the influencing factors, and the forest plot was used to visualize the statistically significant factors.Results Totally 23 358 eligible small-cell lung cancer patients were included. According to the age analysis results of X-Tile software, they were divided into three groups: ≤65 years old, 66-years old and ≥80 years old. There were statistically significant differences in gender, AJCC cancer stage, surgery, radiotherapy and chemotherapy, bone metastasis, brain metastasis, lung metastasis and tumor size among patients of different age groups (P<0.05). Demographic characteristics (race, gender, family income, insurance, and marital status), AJCC stage, treatment (surgery, radiotherapy, and chemotherapy), metastasis (bone, brain, liver and lung metastasis), and tumor size had statistically significant difference in prognosis for those below 80 years old (P<0.05).AJCC stage, treatment (surgery, radiotherapy, and chemotherapy), metastasis (brain metastasis and liver metastasis), and tumor size had statistically significant difference in prognosis for those 80 years old and above (P<0.05), while demographic characteristics (race, gender, family income, and marital status) had no significant difference in prognosis (P>0.05).Conclusion The clinical characteristics of small cell lung cancer patients in different age groups are not all the same, and the prognostic factors are also different. Demographic characteristics, AJCC staging, treatment, metastasis and tumor size are the main influence factors of prognosis for relatively young patients; demographic characteristics are no longer the main factors that affect the prognosis for older patients. It is suggested that different measures should be taken to improve the prognosis of patients of different ages according to the main influencing factors.

Key words： small cell lung cancer clinical feature prognosis cox proportional hazard model

Received: 09 April 2022

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Rong
	Shen Huanhuan
	Xie Shuyang
	Zhao Zhenjun

Cite this article:

Wang Rong,Shen Huanhuan,Xie Shuyang, et al. Analysis of clinical features and prognostic factors of small cell lung-cancer-in different age groups[J]. journal1, 2022, 29(4): 246-252.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2022.04.002 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2022/V29/I4/246

［1］SALTOS A, SHAFIQUE M, CHIAPPORI A. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)［J］. Front Oncol, 2020, 10: 1074. DOI:10.3389/fonc.2020.01074.
［2］TSOUKALAS N, ARAVANTINOUFATOROU E, BAXEVANOS P, et al. Advanced small cell lung cancer (SCLC):New challenges and new expectations［J］. Ann Transl Med, 2018, 6(8):145. DOI:10.21037/atm.2018.03.31.
［3］HE J X, XU S H, PAN H, et al. Treatments for combined small cell lung cancer patients［J］. Transl Lung Cancer Res, 2020, 9(5):1785-1794. DOI:10.21037/tlcr-20-437.
［4］ZHANG R S, CAI L, WANG G M, et al. Resection of early-stage second primary non-small cell lung cancer after small cell lung cancer: A population-based study［J］. Front Oncol, 2019, 9:1552. DOI:10.3389/fonc.2019.01552.
［5］PAXIMADIS P, BEEBEDIMMER J L, GEORGE J, et al. Comparing treatment strategies for stage I small-cell lung cancer［J］. Clin Lung Cancer, 2018, 19(5):e559-e565. DOI:10.1016/j.cllc.2018.03.017.
［6］DESANTIS C E, MILLER K D, DALE W, et al. Cancer statistics for adults aged 85 years and older, 2019［J］. CA Cancer J Clin, 2019, 69(6):452-467. DOI:10.3322/caac.21577.
［7］NIGHTINGALE G, SCHWARTZ R, KACHUR E, et al. Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects［J］. J Geriatr Oncol, 2019, 10(1):4-30. DOI:10.1016/j.jgo.2018.06.008.
［8］NI M, JIANG A J, LIU W J, et al. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: A multi-center study［J］. Radiat Oncol, 2020, 15(1):70. DOI:10.1186/s13014-020-01509-3.
［9］SALTOS A, SHAFIQUE M, CHIAPPORI A. Update on the biology, management, and treatment of small cell lung cancer (SCLC)［J］. Front Oncol, 2020, 10:1074. DOI:10.3389/fonc.2020.01074.
［10］LI N, CHU Y X, SONG Q B. Brain metastasis in patients with small cell lung cancer［J］. Int J Gen Med, 2021, 14:10131-10139. DOI:10.2147/IJGM.S342009.
［11］O′KEEFFE L M, TAYLOR G, HUXLEY R R, et al. Smoking as a risk factor for lung cancer in women and men: A systematic review and metaanalysis［J］. BMJ Open, 2018, 8(10):e021611. DOI:10.1136/bmjopen-2018-021611.
［12］ZENG C, LI N N, LI F, et al. Prognostic factors of patients with small cell lung cancer after surgical treatment［J］. Ann Transl Med, 2021, 9(14):1146. DOI:10.21037/atm-21-2912.
［13］ZHOU K X, SHI H S, CHEN R Q, et al. Association of race, socioeconomic factors, and treatment characteristics with overall survival in patients with limited-stage small cell lung cancer［J］. JAMA Netw Open, 2021, 4(1):e2032276. DOI:10.1001/jamanetworkopen.2020.32276.
［14］GAO Z Y, REN F G, SONG H, et al. Marital status and survival of patients with chondrosarcoma: A population-based analysis［J］. Med Sci Monit, 2018, 24:6638-6648. DOI:10.12659/MSM.911673.
［15］LIU Y, XIN Y, ZHU J, et al. A retrospective analysis of prognostic factors for 160 patients with stage III small cell lung cancer［J］. Ann Palliat Med, 2021, 10(6):6189-6197. DOI:10.21037/apm-21-50.
［10］WANG Y Y, ZHENG Q W, JIA B, et al. Effects of surgery on survival of early-stage patients with SCLC: Propensity score analysis and nomogram construction in SEER database［J］. Front Oncol, 2020, 10:626. DOI:10.3389/fonc.2020.00626.
［17］ZHAO Y, ZHANG X, JIN C X, et al. Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: A phase 2 single-arm multicenter open-label trial［J］. Ann Palliat Med, 2021, 10(3):3277-3285. DOI:10.21037/apm-21-443.
［18］HORN L, MANSFIELD A S, SZCZ〖KG-*3〗〖XCE.TIF〗〖KG-*8〗SNA A, et al. Firstline atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer［J］. N Engl J Med, 2018, 379(23):2220-2229. DOI:10.1056/NEJMoa1809064.
［19］PAZ-ARES L, DVORKIN M, CHEN Y B, et al. Durvalumab plus platinumetoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):A randomised, controlled, open-label, phase 3 trial［J］. Lancet, 2019, 394(10212):1929-1939. DOI:10.1016/S0140-6736(19)32222-6.